Home > Cardiology > EHRA 2022 > Other Topics > Updates on anti-arrhythmic agents

Updates on anti-arrhythmic agents

Presented By
Prof. John Camm, St George’s University of London, UK
Presented by
John Camm St George’s University of London
EHRA 2022
The INSTANT study showed that oral inhalation of flecainide restored sinus rhythm in patients with recent-onset atrial fibrillation. In the NODE-301 trial, etripamil nasal spray showed to significantly improve paroxysmal supraventricular tachycardia-related symptoms. Small-conductance calcium-activated potassium channel inhibitors showed to delay the cardiac action potential and seem to be atrial selective. Sulcardine reduced the J-Tp interval, a feature only seen for this agent. The GENETIC-AF trial showed a preventive effect of bucindolol on new-onset atrial fibrillation (AF), and, finally, botulinum toxin A delayed postoperative AF after injection. Prof. John Camm (St George’s University of London, UK) discussed the latest evidence concerning the development of novel anti-arrhythmic drugs (AAD) and corresponding administration methods [1]. Inhaled flecainide for AF is currently being tested in the phase 2 INSTANT study (

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on